Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

被引：15

作者：

Haworth, Charles S. ^{[1
]}

Sharples, Linda ^{[2
]}

Hughes, Vikki

Elkin, Sarah L. ^{[3
,4
]}

Hodson, Margaret E. ^{[3
]}

Conway, Steven P. ^{[5
]}

Etherington, Christine ^{[5
]}

Elborn, J. Stuart ^{[6
]}

Rendall, Jackie ^{[6
]}

Wheaton, Ella ^{[2
]}

Kadri, Emma ^{[7
]}

Elliott, Jane ^{[1
]}

Barker, Helen C. ^{[1
]}

Bearcroft, Philip W. P. ^{[8
]}

Hlaing, Thinn ^{[9
]}

Compston, Juliet E. ^{[10
]}

机构：

[1] Papworth Hosp, Adult Cyst Fibrosis Ctr, Cambridge CB23 3RE, England

[2] Inst Publ Hlth, MRC Biostat Unit, Cambridge CB2 OSR, England

[3] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, NHLI, London SW3 6LY, England

[4] St Marys Hosp, Dept Resp Med, London W2 1NY, England

[5] St James Univ Hosp, Adult Cyst Fibrosis Ctr, Leeds LS9 7TF, W Yorkshire, England

[6] Belfast City Hosp, Adult Cyst Fibrosis Ctr, Belfast BT9 7AB, Antrim, North Ireland

[7] Papworth Hosp, Dept Pharm, Cambridge CB23 3RE, England

[8] Addenbrookes Hosp, Dept Radiol, Cambridge CB2 OQQ, England

[9] Addenbrookes Hosp, Dept Biochem, Cambridge CB2 OQQ, England

[10] Univ Cambridge, Dept Med, Cambridge CB2 OQQ, England

来源：

JOURNAL OF CYSTIC FIBROSIS | 2011年 / 10卷 / 06期

关键词：

Bone mineral density; Cystic fibrosis; Fractures; Osteoporosis; MINERAL DENSITY; INTRAVENOUS PAMIDRONATE; DOUBLE-BLIND; OSTEOPOROSIS; ALENDRONATE; EFFICACY; THERAPY; QUALITY; PAIN; CF;

D O I：

10.1016/j.jcf.2011.07.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1 g)+ vitamin D(3) (800 IU). Results: At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41. Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：470 / 476

页数：7

共 29 条

[1] Efficacy of alendronate in adults with cystic fibrosis with low bone density [J].

Aris, RM ;

Lester, GE ;

Caminiti, M ;

Blackwood, AD ;

Hensler, M ;

Lark, RK ;

Hecker, TM ;

Renner, JB ;

Guillen, U ;

Brown, SA ;

Neuringer, IP ;

Chalermskulrat, W ;

Ontjes, DA .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (01) :77-82

[2] Consensus statement: Guide to bone health and disease in cystic fibrosis [J].

Aris, RM ;

Merkel, PA ;

Bachrach, LK ;

Borowitz, DS ;

Boyle, MP ;

Elkin, SL ;

Guise, TA ;

Hardin, DS ;

Haworth, CS ;

Holick, MF ;

Joseph, PM ;

O'Brien, K ;

Tullis, E ;

Watts, NB ;

White, TB .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1888-1896

[3] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[4] Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis [J].

Buntain, HM ;

Schluter, PJ ;

Bell, SC ;

Greer, RM ;

Wong, JCH ;

Batch, J ;

Lewindon, P ;

Wainwright, CE .

THORAX, 2006, 61 (02) :146-154

[5] Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF) [J].

Chapman, Ian ;

Greville, Hugh ;

Ebeling, Peter R. ;

King, Susannah J. ;

Kotsimbos, Tom ;

Nugent, Patricia ;

Player, Rosie ;

Topliss, Duncan J. ;

Warner, Janet ;

Wilson, John W. .

CLINICAL ENDOCRINOLOGY, 2009, 70 (06) :838-846

[6]

Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO

[7]

2-K

[8] Compliance with osteoporosis therapy is the weakest link [J].

Compston, Juliet E. ;

Seeman, Ego .

LANCET, 2006, 368 (9540) :973-974

[9] DXA longitudinal quality control: A comparison of inbuilt quality assurance, visual inspection, multi-rule Shewhart charts and Cusum analysis [J].

Garland, SW ;

Lees, B ;

Stevenson, JC .

OSTEOPOROSIS INTERNATIONAL, 1997, 7 (03) :231-237

[10] Assessment of prevalent and incident vertebral fractures in osteoporosis research [J].

Genant, HK ;

Jergas, M .

OSTEOPOROSIS INTERNATIONAL, 2003, 14 (Suppl 3) :S43-S55

← 1 2 3 →